833 results about "Nitroso" patented technology

Disclosed herein are methods and compositions for modulating the levels and / or activity of S-nitrosoglutathione reductase (GSNOR) in vivo or in vitro. Specifically disclosed are GSNOR deletion constructs, host cells and non-human mammals comprising GSNOR deletions, and methods of screening employing GSNOR deletion mutants. Also specifically disclosed are reagents and procedures for measuring, monitoring, or altering GSNOR levels or activity (as well as nitric oxide and S-nitrosothiol levels) in connection with various medical conditions.

The invention discloses a PVC foam wood / plastic composite material and relates to the technical field of composite materials. The PVC foam wood / plastic composite material is made from the following raw materials in parts by weight: 20-70 parts of PVC resin powder, 0-55 parts of wood flour, 5-40 parts of calcium carbonate powder, 0.1-0.5 part of sodium bicarbonate, 0.3-0.6 part of an azo-compound or hydrazine derivative, semicarbazide compound or nitroso-compound, 2-10 parts of a foaming regulator, 1.5-6 parts of a composite stabilizer, 0.7-2.1 parts of a lubricant, 0.5-1.2 part of soybean oil, 2.5-5.5 parts of an impact modifier, and 0.5-3 parts of a processing agent. The PVC foam wood / plastic composite material provided by the invention has the advantages of strong chemical stability, high strength, resistance to acid / alkaline corrosion, resistance to water seepage, flame retardancy and low cost.

A functionalized polymer includes a polymer chain and, bonded thereto, a functional group having the general formula —NQOR1 where R1 is a hydrogen atom or —CH2Z where Z is a hydrogen atom or a substituted or unsubstituted aryl, alkyl, alkenyl, alkenaryl, aralkenyl, alkaryl, or aralkyl group and where Q is a moiety connected to the nitrogen atom of the functional group through a C, N, O, or S atom. The material can be the reaction product of a living polymer and a compound that includes nitroso functionality. The functional group can interact with particulate filler such as, e.g., carbon black.

Assays for identifying compounds that modulate, preferably inhibit bitter taste associated with the activation of hT2R4, hT2R44 and / or hT2R61 are provided. The compounds identified according to these assays should modulate, e.g., inhibit bitter taste associated with bitter tasting compounds including quinine, 6-nitrosaccharin, saccharin and / or denatonium. These compounds are useful additives for foods, beverages or medicinal preparationshaving a bitter taste.

The invention describes novel nitrosated and / or nitrosylated compounds of the invention and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and / or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor and / or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, and at least one nitric oxide donor and / or at least one therapeutic agent. The invention also provides novel kits comprising at least one compound of the invention, that is optionally nitrosated and / or nitrosylated, and, optionally, at least one nitric oxide donor and / or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. The nitrosated and / or nitrosylated compounds of the invention are preferably nitrosated and / or nitrosylated antimicrobial compounds, nitrosated and / or nitrosylated adenosine antagonists, nitrosated and / or nitrosylated LTB4 antagonists, nitrosated and / or nitrosylated mucoregulators and nitrosated and / or nitrosylated purine agonists. The methods of the invention are preferably for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis.

A skin dressing is adapted, on activation, to release one or more S-nitrosothiols, preferably S-nitroso-L-glutathione. S-nitrosothiols decompose spontaneously to produce nitric oxide, which has beneficial effects on tissues, particularly in wound healing.

A C-nitroso compound having a molecular weight ranging from about 225 to about 1,000 (from about 225 to about 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained by nitrosylation of a carbon acid having a pKa less than about 25, is useful as an NO donor. In another case, the C-nitroso compound contains the moiety—C—N(O)X—where X is S, O or NR. One embodiment is directed to COX-2 inhibitors where a tertiary carbon atom and / or an oxygen atom and / or a sulfur atom is nitrosylated.

Sports equipment incorporate thermoplastic compositions including urethane and a nitroso reaction product of a nitroso compound and a diisocyanate or polyisocyanate. The invention allows for the processing advantages of a thermoplastic urethane with the superior performance characteristics of a cross-linked polyurethane.

The invention describes novel nitrosated and / or nitrosylated diuretic compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and / or nitrosylated diuretic compound, and, optionally, at least one nitric oxide donor and / or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one diuretic compound of the invention, that is optionally nitrosated and / or nitrosylated, and, optionally, at least one nitric oxide donor compound and / or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and / or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; and (l) treating nephropathy.

A C-nitroso compound having a molecular weight ranging from 225 to 1,000 (from 225 to 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained by nitrosylation of a carbon acid having a pKa less than about 25, is useful as an NO donor. When the compound is obtained from a carbon acid with a pKa less than about 10, it provides vascular relaxing effect when used at micromolar concentrations and this activity is potentiated by glutathione to be obtained at nanomolar concentrations. When the compound is obtained from a carbon acid with a pKa ranging from about 15 to about 20, vascular relaxing effect is obtained at nanomolar concentrations without glutathione. In another embodiment, a biocompatible polymer incorporates a C-nitroso moiety.

A functionalized polymer includes a polymer chain and, bonded thereto, a functional group having the general formula —NQOR1 where R1 is a hydrogen atom or —CH2Z where Z is a hydrogen atom or a substituted or unsubstituted aryl, alkyl, alkenyl, alkenaryl, aralkenyl, alkaryl, or aralkyl group and where Q is a moiety connected to the nitrogen atom of the functional group through a C, N, O, or S atom. The material can be the reaction product of a living polymer and a compound that includes nitroso functionality. The functional group can interact with particulate filler such as, e.g., carbon black.

A method for preparing a functionalized polymer, the method comprising the steps of: (i) polymerizing monomer with a coordination catalyst to form a reactive polymer; and (ii) reacting the reactive polymer with a nitroso compound.

Novel 2- and 4-substituted pyrimidine nucleosides and oligonucleosides are provided, as are methods and intermediates useful in preparing same. In preferred embodiments, one of the 2- and 4-substituents is =O, =NH, or =NH2+ and the other is Q, =C (RA)-Q, C(RA)(RB)-C(RC)(RD)-Q, C (RA)=C(RC)-Q or C 3BOND C-Q, where RA, RB, RC and RD independently are H, SH, OH, NH2, or C1-C20 alkyl, or one of (RA)(RB) or (RC)(RD) is =O, and Q is halogen, hydrogen, C1-C20 alkyl, C1-C20 alkylamine, C1-C20 alkyl-N-phthalimide, C1-C20 alkylimidazole, C1-C20 alkylbis-imidazole, imidazole, bis-imidazole, amine, N-phthalimide, C2-C20 alkenyl, C2-C20 alkynyl, hydroxyl, thiol, keto, carboxyl, nitrates, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aralkyl, S-aralkyl, NH-aralkyl, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, O-(hydroxyl protecting group), a leaving group, a heterocycle, an intercalator, a reporter molecule, a conjugate, a polyamine, a polyamide, a polyethylene glycol, a polyether, or a depurination enhancing group.

Sports equipment incorporate thermoplastic compositions including urethane and a nitroso reaction product of a nitroso compound and a diisocyanate or polyisocyanate. The invention on allows for the processing advantages of a thermoplastic urethane with the superior performance characteristics of a cross-linked polyurethane.

A C-nitroso compound having a molecular weight ranging from 225 to 1,000 (from 225 to 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained by nitrosylation of a carbon acid having a pKa less than about 25, is useful as an NO donor. When the compound is obtained from a carbon acid with a pKa less than about 10, it provides vascular relaxing effect when used at micromolar concentrations and this activity is potentiated by glutathione to be obtained at nanomolar concentrations. When the compound is obtained from a carbon acid with a pKa ranging from about 15 to 20, vascular relaxing effect is obtained at nanomolar concentrations without glutathione. In another embodiment, a biocompatible polymer incorporates a C-nitroso moiety.

The invention relates to a method for degrading organic pollutants in water by gradient ozone catalytic oxidation, and relates to a gradient ozone catalytic oxidation combination method for degrading organic pollutants in water. By the method, the problem that the conventional advanced oxidation technology has defects during individual use, the problem that the organic pollutants in the water cannot be removed efficiently, the problem that the influence of the pH value and temperature of the water on the method is large, and the problem that high-toxicity byproducts are formed are solved. In the method, water treatment is realized by combining two or three of a process for treating O3 individually, an enhanced catalytic oxidation process for O3 and an O3 / ultraviolet (UV) process sequentially. By the reasonable optimizing and gradient combination of the three treatment modes, the method is suitable for wide pH values and a wide temperature range, the pollutants with intermediate toxicity are controlled to be formed, the toxicity of the pollutants is reduced, the pollutants in the water is degraded efficiently and completely, and the content of oxidative species in effluent is controlled. An efficient oxidation treatment effect is kept at low temperature, and the generation of bromate, nitroso dimethylamine, chlorate, perchlorate, iodate and periodate can be controlled greatly.

The invention provides a method for polishing one or more layers of a multi-layer substrate that includes a first metal layer and a second layer comprising (i) contacting the first metal layer with a polishing system comprising a liquid carrier, at least one oxidizing agent, at least one polishing additive that increases the rate at which the system polishes at least one layer of the substrate, wherein the polishing additive is selected from the group consisting of pyrophosphates, condensed phosphates, phosphonic acids and salts thereof, amines, amino alcohols, amides, imines, imino acids, nitriles, nitros, thiols thioesters, thioethers, carbothiolic acids, carbothionic acids, thiocarboxylic acids, thiosalicylic acids, and mixtures thereof, and a polishing pad and / or an abrasive, and (ii) polishing the first metal layer with the system until at least a portion of the first metal layer is removed from the substrate.

Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in Nicotiana plants and plant parts thereof are provided. The compositions comprise isolated polynucleotides and polypeptides for cytochrome P450s that are involved in the metabolic conversion of nicotine to nornicotine in these plants. Expression cassettes, vectors, plants, and plant parts thereof comprising inhibitory sequences that target expression or function of the disclosed cytochrome P450 polypeptides are also provided. Methods for the use of these novel sequences to inhibit expression or function of cytochrome P450 polypeptides involved in this metabolic conversion are also provided. The methods find use in the production of tobacco products that have reduced levels of nornicotine and its carcinogenic metabolite, NNN, and thus reduced carcinogenic potential for individuals consuming these tobacco products or exposed to secondary smoke derived from these products.

The present invention relates to a battery comprising at least a positive electrode, a negative electrode and an electrolyte as composing elements, wherein the positive electrode and / or the negative electrode comprise an active material of nitroxyl radical compound represented by the following general formula (1) as a starting material or a reaction product of at least a discharge reaction of electrode reactions: wherein Ar represents substituted or unsubstituted aromatic heterocyclic group containing nitrogen wherein one endocyclic nitrogen atom or at least one of plural endocyclic nitrogen atoms exists as N-oxide; the substituent R1 represents hydrogen atom, halogen atom, hydroxyl group, nitro group, nitroso group, cyano group, carboxyl group, substituted or unsubstituted alkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted aralkyl group, substituted or unsubstituted amino group, substituted or unsubstituted alkoxy group, substituted or unsubstituted aryloxy group, substituted or unsubstituted alkoxycarbonyl group, substituted or unsubstituted aryloxycarbonyl group, or substituted or unsubstituted acyl group, wherein one or more of the atoms may be substituted with sulfur atom, silicon atom, phosphorus atom or boron atom; R1 may be the identical with Ar and a ring structure may be formed between R1 and Ar.

The invention relates to an in-vitro detection reagent for clinical diagnosis, particularly a reagent for determining metabolic disorder in a human body, particularly a p-hydroxy phenylalanine urine detection reagent and a preparation method thereof. The urine detection reagent is prepared by respectively dissolving Hg2<+>, Hg<2+>, Ni<2+> and alpha-nitroso-beta-naphthol in corresponding acid solutions and proportionally mixing. The mercuric sulfate is dissolved in a sulfuric acid solution as a donor of Hg<2+>, the mercurous nitrate is dissolved in a nitric acid solution as a donor of Hg2<+>, the nickel sulfate is dissolved in distilled water as a donor of Ni<2+>, and the alpha-nitroso-beta-naphthol is dissolved in a nitric acid solution. The invention overcomes the defects in the prior art, and provides a new-formula metabolic disorder quick urinalysis reagent which has the advantages of high stability, high sensitivity and wide application range.

The present invention describes novel nitrosated and / or nitrosylated potassium channel activators, and novel compositions comprising at least one nitrosated and / or nitrosylated potassium channel activator, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one potassium channel activator, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or at least one vasoactive agent. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cardiovascular disorders, cerebrovascular disorders, hypertension, asthma, baldness, urinary incontinence, epilepsy, sleep disorders, gastrointestinal disorders, migraines, irritable bowel syndrome and sensitive skin.

The present invention relates to surface modifying agents for polymeric and / or textile materials, methods of making and / or using a surface modifying agent to modify and functionalize polymeric and / or textile materials, and / or methods of using surface modified or functionalized polymeric and textile materials, and / or products using or incorporating surface modified or functionalized polymeric and textile materials. For example, the surface modifying agent in precursor form can be styrene sulfonyl azide monomer, polymer or copolymer capable of undergoing a chemical reaction in the presence of heat or light to form one or more styrene sulfonated nitrene monomers, polymers or copolymers, which are capable of chemically reacting with the surface of a polymeric or textile material to endow a specific or desired chemical surface functionality to the surface of a polymeric or textile material. Furthermore, the present invention is possibly preferably directed to a surface modifying agent which comprises a styrene sulfonated nitrene monomer, polymer or polymer containing one or more nitrene functional groups, which are capable of chemically reacting via an insertion reaction into one or more carbon-hydrogen bonds on the surface of a polymeric or textile material in order to chemically attach a specific or desired chemical functionality to the surface of a polymeric or textile material.

Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-heme proteins, S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoproteins; and S-nitroso-immunoglobulins. The invention also relates to therapeutic use if S-nitroso-protein compounds for regulating protein function, cellular metabolism and effecting vasodilation, platelet inhibition, relaxation of non-vascular smooth muscle, and increasing blood oxygen transport by hemoglobin and myoglobin. The compounds are also used to deliver nitric oxide in its most bioactive form in order to achieve the effects described above, or for in vitro nitrosylation of molecules present in the body. The invention also relates to the nitrosylation of oxygen, carbon and nitrogen moieties present on proteins and amino acids, and the use thereof to achieve the above physiological effects.

The invention provides a method for preparing 4-amino diphenylamine by catalytic hydrogenation. The method adopts two sections of hydrogenation reaction processes, and comprises the following steps: performing the condensation reaction of condensation solution formed by the condensation reaction of nitrobenzene and aniline which serve as raw materials under an alkaline condition by using using a noble metal hydrogenation catalyst and a nickel catalyst sequentially so as to make the conversion rate of 4-nitroso diphenylamine, 4-nitro diphenylamine and azoxybenzene achieve 100 percent; and separating the noble metal hydrogenation catalyst and the nickel catalyst by using a two-stage membrane separation component system to avoid the loss of small particles of catalyst. At the same time, the method has high degree of automation and can easily realize the continuous hydrogenation process.

The invention belongs to the field of medicines, relates to anti-tumor medicines, and in particular relates to anti-tumor medicines in double-aryl urea structures based on indazole, indole, azaindazole or azaindole. The structural formulae of the anti-tumor medicines are shown in formula (Ia) and formula (Ib), wherein Z is N atom or C atom; W is O; M is O, S, N or CH; n is 1 or 2; Y and R are halogen atoms, H, R1, CF3, OCF3, OH, OR2, OCOR3, NH2, NHR4, NR52, NHCOR6, carboxyl group, ester group, cyano group, mercapto group, alkyl sulphanyl, sulfuryl, sulfoxide, sulfonic group, sulfamate, sulfonamide, ketonic group, aldehyde group, nitro group or nitroso group. Pharmacodynamic experiments prove that the medicines have good anti-tumor effects on human lung cancer, human kidney cancer, human colon cancer, human liver cancer, human gastric cancer, human breast cancer, melanoma and the like.

Disclosed herein is a method for inhibiting and retarding the premature polymerization and the polymer growth of vinyl aromatic monomers wherein the method comprises adding to said monomers an effective amount of an inhibitor and retarder blend comprising: (A) at least one aromatic sulfonic acid; (B) at least one amine; (C) at least one nitrophenol; and (D) at least one member of the group consisting of nitroxy radical-containing compounds and nitrosoanilines.